{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:36:37Z","timestamp":1788572197586,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":613,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1093\/annonc\/mdy019","type":"journal-article","created":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T20:09:12Z","timestamp":1516997352000},"page":"578-587","source":"Crossref","is-referenced-by-count":39,"title":["Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia"],"prefix":"10.1016","volume":"29","author":[{"given":"H.J.","family":"Khoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdy019_bb0010","unstructured":"BosulifTM (bosutinib). Summary of Product Characteristics. Pfizer Inc, Sandwich, Kent, UK, 2013."},{"key":"10.1093\/annonc\/mdy019_bb0015","unstructured":"Bosulif\u00ae (bosutinib). Full Prescribing Information, Pfizer Labs, Pfizer Inc, New York, NY, USA, 2017."},{"issue":"17","key":"10.1093\/annonc\/mdy019_bb0020","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1093\/annonc\/mdy019_bb0025","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.23728","article-title":"Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1093\/annonc\/mdy019_bb0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bjh.13801","article-title":"Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib","volume":"172","author":"Brummendorf","year":"2016","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1093\/annonc\/mdy019_bb0035","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"123","author":"Kantarjian","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1093\/annonc\/mdy019_bb0040","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1093\/annonc\/mdy019_bb0045","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ajh.24034","article-title":"Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance\/intolerance to imatinib and other tyrosine kinase inhibitors","volume":"90","author":"Gambacorti-Passerini","year":"2015","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1093\/annonc\/mdy019_bb0050","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/ajh.24536","article-title":"Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"issue":"28","key":"10.1093\/annonc\/mdy019_bb0055","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy019_bb0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Br\u00fcmmendorf","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1093\/annonc\/mdy019_bb0065","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1634\/theoncologist.2013-0294","article-title":"The European Medicines Agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use","volume":"19","author":"Hanaizi","year":"2014","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdy019_bb0070","first-page":"S316","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"17","author":"Cortes","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy019_bb0075","first-page":"99","article-title":"Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia","volume":"6","author":"Amsberg","year":"2013","journal-title":"Onco Targets Ther"},{"issue":"6","key":"10.1093\/annonc\/mdy019_bb0080","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.24360","article-title":"Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"issue":"35","key":"10.1093\/annonc\/mdy019_bb0085","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy019_bb0090","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdy019_bb0095","doi-asserted-by":"crossref","first-page":"E184","DOI":"10.1002\/ajh.23804","article-title":"First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis","volume":"89","author":"Vigano","year":"2014","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1093\/annonc\/mdy019_bb0100","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1093\/annonc\/mdy019_bb0105","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12185-014-1722-8","article-title":"A phase 1\/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia","volume":"101","author":"Nakaseko","year":"2015","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1093\/annonc\/mdy019_bb0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00280-012-1987-7","article-title":"Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects","volume":"71","author":"Abbas","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1093\/annonc\/mdy019_bb0115","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1177\/0091270010387427","article-title":"Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects","volume":"51","author":"Abbas","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1093\/annonc\/mdy019_bb0120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00280-011-1688-7","article-title":"A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects","volume":"69","author":"Abbas","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1093\/annonc\/mdy019_bb0125","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.clinthera.2012.07.006","article-title":"Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects","volume":"34","author":"Abbas","year":"2012","journal-title":"Clin Ther"},{"issue":"8","key":"10.1093\/annonc\/mdy019_bb0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40261-013-0103-z","article-title":"A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects","volume":"33","author":"Abbas","year":"2013","journal-title":"Clin Drug Investig"},{"issue":"10","key":"10.1093\/annonc\/mdy019_bb0135","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajh.23788","article-title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdy019_bb0140","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ajh.23973","article-title":"Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program","volume":"90","author":"Garcia-Gutierrez","year":"2015","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1093\/annonc\/mdy019_bb0145","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clml.2017.06.001","article-title":"Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1093\/annonc\/mdy019_bb0150","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mdy019_bb0155","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdy019_bb0160","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Ft. Washington, PA: NCCN; 2018."},{"key":"10.1093\/annonc\/mdy019_bb0165","series-title":"Effects of bosutinib dose escalation on gastrointestinal adverse-events In 17th Annual John Goldman Conference on Chronic Myleloid Leukemia Biology and Therapy Estoril Portugal","author":"Kota","year":"2015"},{"key":"10.1093\/annonc\/mdy019_bb0170","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug Iclusig; company expected to resume marketing. Rockville, MD: US FDA; 2013."},{"issue":"7","key":"10.1093\/annonc\/mdy019_bb0175","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1185\/03007995.2014.904281","article-title":"Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase","volume":"30","author":"Guerin","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1093\/annonc\/mdy019_bb0180","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clml.2011.10.004","article-title":"Managing chronic myeloid leukemia: a coordinated team care perspective","volume":"12","author":"Holloway","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419355218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419355218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/3\/578\/24530976\/mdy019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:54:24Z","timestamp":1624697664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419355218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0923753419355218"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy019","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}